Company news

AbbVie Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Correction: AbbVie

March 31, 2026

AbbVie to Host First-Quarter 2026 Earnings Conference Call

March 31, 2026

Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)

March 30, 2026

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

March 27, 2026

Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)

March 26, 2026

Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco

March 26, 2026

Global Botulinum Toxin Market Outlook: AbbVie (Allergan), Ipsen & Revance Lead Aesthetic Growth Across North America

March 25, 2026

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

March 24, 2026

Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®

March 19, 2026

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

March 19, 2026

Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform

March 17, 2026

Allergan Aesthetics Redefines Skin Quality Communication with Launch of Skin Quality Index

March 16, 2026

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

March 9, 2026

Allergan Aesthetics highlights medical weight loss (MWL) data and the changing profile of patients

March 4, 2026

AbbVie to Present at the Leerink Partners Global Healthcare Conference

March 3, 2026

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

March 2, 2026

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

February 23, 2026

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

February 20, 2026

AbbVie Declares Quarterly Dividend

February 19, 2026

Facial Injectable Analysis Report 2025: An $18.89 Billion Market by 2029, Driven by New Product Launches, Emerging Markets, AI Innovations, Male Aesthetics, Younger Demographics

February 17, 2026

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

February 4, 2026

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

February 3, 2026

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

January 29, 2026

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

January 28, 2026

Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference

January 21, 2026

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

January 16, 2026

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

January 12, 2026

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

January 12, 2026

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

January 7, 2026

MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus

January 6, 2026

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List

December 14, 2025

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development

December 8, 2025

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

December 2, 2025

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

November 28, 2025

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

November 25, 2025

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

November 24, 2025

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

November 18, 2025

LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer

November 17, 2025

AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer

November 14, 2025

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

November 13, 2025

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

November 12, 2025

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

November 12, 2025

Calico Life Sciences Announces U.S. FDA Orphan Drug Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease

November 5, 2025

AbbVie Reports Third-Quarter 2025 Financial Results

October 31, 2025

ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers

October 30, 2025

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

October 29, 2025

Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM

October 28, 2025

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

October 21, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 24 decks. Every deck is listed under its year.